What Bionaut Labs does

Bionaut Labs is a US-based, privately held medical technology company founded in 2016 and headquartered in Los Angeles. The company develops microscale robots (microrobots) designed to navigate inside the human skull and central nervous system to deliver targeted treatments for brain and spinal cord disorders. Its core technology is a miniaturized robotic platform capable of reaching anatomical regions that are inaccessible through conventional neurosurgical or systemic drug delivery approaches, enabling precise, localized, and minimally invasive treatment of CNS diseases.

The company is in the clinical research stage and has not yet commercialized its platform. Its target customer segment is healthcare providers and research institutions specializing in neurology and neurosurgery. The anticipated commercial model involves medical device sales or treatment delivery services to hospitals and neurosurgical centers, with pricing not publicly disclosed. To date, the company has been funded entirely through venture capital, raising approximately $63.2 million in cumulative funding across multiple rounds, including a $43.2 million Series B led by Khosla Ventures in November 2022, with additional participation from Bold Capital Partners, Upfront Ventures, Compound, Revolution, Dolby Family Ventures, and others. Leadership includes CEO and co-founder Michael Shpigelmacher, co-founder Aviad Maizels, CSO Alex Kiselyov, CTO Eran Oren, VP of Neuroscience William Loudon, and SVP of Clinical Development and Medical Affairs Meeta Patnaik.

Name

Bionaut Labs

Legal name

Bionaut Labs

Website

https://bionautlabs.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Bionaut Labs develops microscale robots for targeted treatment of central nervous system disorders, navigating inside the human skull to deliver precise, minimally invasive therapies for brain and spinal cord diseases. The company serves healthcare providers and research institutions in the clinical research stage.

Ownership category

akta.pro rank

Product category

Medical Robotics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)

akta.pro secondary industry

Robot Hardware, Actuators & Components (sensors, grippers, motors) (HDAAAIAL)

Keywords

• Microscale medical robots
• Central nervous system treatment
• Neurosurgical robotics
• Precision drug delivery
• Brain-spine therapeutics

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device/Treatment Platform: Bionaut Labs is developing a microscale robot platform for medical treatments. The company is in the clinical research stage with platform expansion underway, indicating a future commercial model likely involving medical device sales or treatment delivery services to healthcare providers.

Go-to-market motion1 record

Core offering

Bionaut Labs develops microscale robots (microrobots) engineered to navigate inside the human skull and central nervous system for targeted treatment of brain and spinal cord diseases. The clinical-stage platform enables localized, minimally invasive precision delivery to anatomical regions that conventional neurosurgical approaches and systemic drug therapies cannot reach.

Product overview

Bionaut Labs develops a microscale robot platform designed for medical applications within the human skull and central nervous system. The company's core offering consists of microscale robots that can be deployed inside the human body for targeted medical treatments, with a focus on neuroscience and healthcare applications for brain and spinal cord diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Microscale Robots for Central Nervous System Treatment Proprietary microscale robots designed for medical use inside the human skull and central nervous system, intended to deliver targeted treatments for central nervous system diseases including brain and spinal cord disorders. The platform targets healthcare providers and clinical research institutions.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Monteris Medical: Developer of the NeuroBlate minimally invasive robotic laser ablation system for neurosurgery. Most direct peer in minimally invasive robotic neurosurgical intervention, targeting overlapping hospital neurosurgery buyers.
• Renishaw: Manufactures the NeuroMate stereotactic neurosurgical robot used for biopsy and electrode placement. Direct peer in robotic platforms deployed inside the skull for CNS procedures, sharing the same neurosurgical customer base.

Broad incumbents

• Zimmer Biomet (ROSA Brain): Larger medical device incumbent whose ROSA Brain robotic platform assists in neurosurgical procedures. Comparable in that it sells robotic CNS intervention tools to neurosurgeons, though broader portfolio and far greater scale.
• Brainlab: Established medtech incumbent offering neurosurgical planning, navigation, and robotic-assisted cranial platforms. Competes for the same neurosurgery capital budgets and overlaps in minimally invasive cranial intervention.
• Intuitive Surgical: Incumbent leader in robotic-assisted surgery with the Da Vinci platform. Relevant as the dominant reference point for commercial surgical robotics adoption curves, hospital economics, and reimbursement dynamics that Bionaut would ultimately face.
• Medtronic (Mazor Robotics / StealthStation): Diversified medtech incumbent with spinal and cranial robotics platforms (Mazor, StealthStation). Overlaps as a buyer of neurosurgical robotic technology and a potential strategic acquirer of differentiated neurotech assets like Bionaut.

Emerging players

• CMR Surgical: Developer of the Versius surgical robotic system. Comparable as a next-generation surgical robotics company targeting hospital OR buyers; addresses a different surgical specialty but validates the commercial path for robotic-assisted minimally invasive surgery.
• Vicarious Surgical: Publicly listed surgical robotics company developing a combined robotics and VR platform for minimally invasive surgery. Comparable as a venture-backed surgical robotics developer pursuing novel miniaturized approaches to minimally invasive surgery.
• Synchron: Neurotechnology company developing endovascular brain-computer interface technology. Comparable as a venture-backed company deploying novel implantable devices in the CNS vasculature, sharing similar regulatory, neuroscience, and clinical-trial challenges.
• Neuralink: Developer of implantable brain-computer interface devices. Comparable as a high-profile venture-backed company building implantable neurotechnology, sharing the same CNS customer/regulatory landscape and capital-intensive hardware development profile.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds6 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bionaut Labs